Too bad he is not spending the time updating current shareholders on the status of this company's financials, debt level, share structure, patents, legal proceedings, and a host of other issues. I fully expect this interview to be nothing more than the other interviews he has done in the past. It is time for details regarding the business not another overview of autologous stromal vascular fraction cell therapy.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.